Cargando…
GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
The complexities of GSK-3β function and interactions with PI3K/AKT/mTOR signaling, cell cycling, and apoptotic pathways are poorly understood in the context of lymphomagenesis and cancer therapeutics. In this study, we explored the anti-tumor effects of the GSK-3β inhibitor, 9-ING-41, in lymphoma ce...
Autores principales: | Karmali, Reem, Chukkapalli, Vineela, Gordon, Leo I., Borgia, Jeffrey A., Ugolkov, Andrey, Mazar, Andrew P., Giles, Francis J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777742/ https://www.ncbi.nlm.nih.gov/pubmed/29383130 http://dx.doi.org/10.18632/oncotarget.22414 |
Ejemplares similares
-
Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020) -
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells
por: Chukkapalli, Vineela, et al.
Publicado: (2018) -
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019) -
Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()
por: Ugolkov, Andrey, et al.
Publicado: (2017) -
9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
por: Poloznikov, Andrey, et al.
Publicado: (2021)